Asian Growth Companies With High Insider Ownership In May 2025

As global markets navigate a landscape marked by easing trade tensions and fluctuating economic indicators, Asia remains a focal point for investors looking to capitalize on growth opportunities. In this environment, companies with high insider ownership often attract attention as they can signal strong confidence from those who know the business best.

Top 10 Growth Companies With High Insider Ownership In Asia

Click here to see the full list of 620 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Shenzhen Envicool Technology (SZSE:002837)

Simply Wall St Growth Rating: ★★★★★★

Overview: Shenzhen Envicool Technology Co., Ltd. specializes in producing and selling temperature control and energy-saving solutions in China, with a market cap of CN¥23.53 billion.

Operations: The company's revenue primarily comes from its Precision Temperature Control Energy Saving Equipment segment, which generated CN¥4.78 billion.

Insider Ownership: 18.3%

Shenzhen Envicool Technology shows strong growth potential with forecasted revenue and earnings growth rates of 24.9% and 28.1% per year, respectively, outpacing the Chinese market averages. Despite high volatility in its share price recently, the company reported impressive annual sales of CNY 4.59 billion for 2024, up from CNY 3.53 billion in the previous year. However, its dividend yield is not well-covered by free cash flows despite recent affirmations of a cash dividend distribution proposal for shareholders.

• Click here and access our complete growth analysis report to understand the dynamics of Shenzhen Envicool Technology.
• Upon reviewing our latest valuation report, Shenzhen Envicool Technology's share price might be too optimistic.

ApicHope Pharmaceutical Group (SZSE:300723)

Simply Wall St Growth Rating: ★★★★★☆

Overview: ApicHope Pharmaceutical Group Co., Ltd. and its subsidiaries focus on the research, development, production, and sale of pharmaceutical drugs, with a market cap of CN¥17.88 billion.

Operations: The company generates revenue through its core activities in the research, development, production, and sale of pharmaceutical drugs.

Insider Ownership: 19.2%

ApicHope Pharmaceutical Group faces challenges with a recent decline in revenue and net income, reporting CNY 376.96 million in sales for Q1 2025 compared to CNY 622.87 million the previous year. Despite this, the company is expected to grow earnings by 75.32% annually and achieve profitability within three years, surpassing market averages. Revenue growth projections of 22.1% per year indicate robust potential, although high share price volatility remains a concern for investors seeking stability.

• Dive into the specifics of ApicHope Pharmaceutical Group here with our thorough growth forecast report.
• Insights from our recent valuation report point to the potential overvaluation of ApicHope Pharmaceutical Group shares in the market.

GENDA (TSE:9166)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: GENDA Inc. operates amusement arcades under the GiGO brand in Japan and has a market cap of ¥185.43 billion.

Operations: Revenue Segments (in millions of ¥): Amusement arcades: ¥185,432

Insider Ownership: 22.1%

GENDA's recent 2:1 stock split highlights its growth strategy, though profit margins have decreased from 7.5% to 3%. Earnings are forecast to grow at a significant rate of 22.4% annually, outpacing the Japanese market average of 7.5%. Despite high share price volatility and debt not being well-covered by operating cash flow, revenue grew substantially by over double in the past year and is expected to continue growing faster than the market average.

• Delve into the full analysis future growth report here for a deeper understanding of GENDA.
• Our valuation report here indicates GENDA may be overvalued.

Taking Advantage

• Click here to access our complete index of 620 Fast Growing Asian Companies With High Insider Ownership.
• Ready For A Different Approach? AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com